Market Cap
$378.2M
SRZN
Surrozen, Inc./DE
$29.65 ▼ -1.17%
Prev close $30.00Market cap$378.2M
ConsensusStrong Buy
12-mo target$48.40 (+63.3%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)11 New Institutional Positions5 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SRZN right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
43 funds
Inst. Value
$88.2M
Inst. Activity
11 buys / 5 sells
Insider Activity
$3.4M buy / $3.7M sell
Insider Net $
-$330.4K
Social Sentiment
50° Neutral
SEC Reports
3
Press Releases
1
Price chart 30d +31.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 fda
Aug 7, 2026 SEC Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macul
Nasdaq filed a Form 25-NSE on August 7, 2026 to remove from listing and registration the Warrants expiring 8/10/2026 of
25-NSE — Impact 3/10
Jul 22, 2026 Insider
TCG Crossover GP II, LLC sold 162,500 shares
10%+ Owner @ $21.25 ($3.5M)
Jun 30, 2026 Inst.
Point72 Asset Management, L.P. — NEW
664,272 shares ($17.2M)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
394,864 shares ($10.2M)
Jun 15, 2026 Insider
Parker Craig C was granted 1,622 shares
Chief Executive Officer @ $8.11 ($13.2K)
Jun 15, 2026 Insider
May 5, 2026 SEC Williams Charles O was granted 1,666 shares
Chief Operating Officer @ $8.11 ($13.5K)
CEO Parker Craig and COO Charles Williams sold a combined $219K worth of SRZN shares at ~$33.33 per share. The total val
CLUSTER — Impact 2/10
Analyst ratings buy % +4.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 20, 2026 | William Blair | INITIATE | Outperform | 51% |
| Aug 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 21, 2026 | TD Cowen | INITIATE | Buy | 56% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jul 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% |
Price targets
Where 5 covering analysts think SRZN trades over the next 12 months.
$48.40 +63.3% upside Strong Buy
Current$29.64 Low$40.00 Median$52.00 High$54.00 5 analysts
$40.00$54.00
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 2 neutral · avg impact 4.0/10.Plus 1 press releases.
NEUTRAL25-NSE3/10
Nasdaq filed a Form 25-NSE on August 7, 2026 to remove from listing and registration the Warrants ex
Aug 7, 2026
NEUTRALCLUSTER2/10
CEO Parker Craig and COO Charles Williams sold a combined $219K worth of SRZN shares at ~$33.33 per
May 5, 2026
BEARISHS-37/10
Surrozen, Inc. has filed an S-3 shelf registration statement with the SEC, authorizing the potential
Mar 23, 2026
MIXED6/10
Surrozen reported its 2025 financial results, showing a significant increase in net loss to $242.0 m
Mar 23, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
fda
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Sep 25, 2026
short_volume
Short Volume: SRZN — 84.1% short (0.8M / 0.9M)
Short: 788,921 | Exempt: 14,093 | TRF Vol: 938,103 | Short Ratio: 84.1% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: SRZN — 63.2% short (2.4M / 3.8M)
Short: 2,387,885 | Exempt: 16,816 | TRF Vol: 3,780,983 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_interest_report
Short Interest: SRZN up 52% to 2.2M shares
Settlement 2026-09-15 | Days to cover: 12.68 | ≈18.68% of shares outstanding (est.)
Sep 2, 2026
other
Surrozen to Present at Upcoming Healthcare Investor Conferences
Surrozen to Present at Upcoming Healthcare Investor Conferences
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.32 | $-1.33–$-1.30 | 63.4% | +0.0% | 0↑ 2↓ | $0.0B | 3 |
| Next Q | $-0.98 | $-1.31–$-0.80 | 89.8% | +0.0% | 0↑ 2↓ | $0.0B | 3 |
| Current FY | $-9.14 | $-9.14–$-9.14 | — | +0.0% | — | $0.0B | 1 |
| Next FY | $-4.19 | $-5.01–$-3.41 | 54.2% | +0.0% | 0↑ 2↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.320 | — |
| 7d ago | $-1.320 | — |
| 30d ago | $-1.320 | — |
| 60d ago | $-1.295 | -0.025 |
| 90d ago | $-1.295 | -0.025 |
Institutional ownership
Which big funds own SRZN (from quarterly 13F filings) and who is adding or trimming.
43 institutional holders with $88.2M total value (3,426,415 shares) as of 2026-Q2. Top holders: MILLENNIUM, Point72, BlackRock,. Net buying activity: 11 institutions added/increased vs 5 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 683,079 | $17.7M | 20.1% | DOUBLED +557.1% |
| Point72 Asset Management, L.P. | 664,272 | $17.2M | 19.5% | NEW |
| BlackRock, Inc. | 394,864 | $10.2M | 11.6% | DOUBLED +1317.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | 392,550 | $10.2M | 11.6% | DOUBLED +132.2% |
| BALYASNY ASSET MANAGEMENT L.P. | 205,032 | $5.3M | 6.0% | DOUBLED +169.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 201,652 | $5.2M | 5.9% | DOUBLED +206.2% |
| STATE STREET CORP | 133,084 | $3.5M | 3.9% | DOUBLED +380.0% |
| GOLDMAN SACHS GROUP INC | 113,531 | $2.9M | 3.3% | DOUBLED +339.2% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 88,653 | $2.3M | 2.6% | ADD +37.1% |
| TWO SIGMA INVESTMENTS, LP | 71,119 | $1.8M | 2.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | NEW | — | 664,272 | — | $17.2M |
| BlackRock, Inc. | DOUBLED | 27,851 | 394,864 | +1317.8% | $10.2M |
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | 169,092 | 392,550 | +132.2% | $10.2M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 65,849 | 201,652 | +206.2% | $5.2M |
| STATE STREET CORP | DOUBLED | 27,726 | 133,084 | +380.0% | $3.5M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 25,851 | 113,531 | +339.2% | $2.9M |
| NORTHERN TRUST CORP | DOUBLED | 12,265 | 63,609 | +418.6% | $1.7M |
| VANGUARD FIDUCIARY TRUST CO | ADD | 35,390 | 59,575 | +68.3% | $1.5M |
| UBS Group AG | ADD | 21,247 | 29,229 | +37.6% | $758.5K |
| FRED ALGER MANAGEMENT, LLC | TRIM | 71,697 | 24,004 | -66.5% | $622.9K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 36 transactions. Net -$330.4K — $3.4M bought, $3.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 22, 2026 | TCG Crossover GP II, LLC | 10%+ Owner | SELL | 162,500 | $21.25 | $3.5M |
| Jun 15, 2026 | Parker Craig C | Chief Executive Officer | AWARD | 1,622 | $8.11 | $13.2K |
| Jun 15, 2026 | Williams Charles O | Chief Operating Officer | AWARD | 1,666 | $8.11 | $13.5K |
| Jun 15, 2026 | Li Yang | Exec. Vice President, Research | AWARD | 1,666 | $8.11 | $13.5K |
| Jun 15, 2026 | Maleki Andrew Pedrum | Chief Financial Officer | AWARD | 607 | $19.01 | $11.5K |
| May 13, 2026 | WOODHOUSE DAVID J | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | Berkenblit Anna | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | BJERKHOLT ERIC | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | CHAI CHRISTOPHER Y | Director | AWARD | 5,550 | — | — |
| May 13, 2026 | Haak-Frendscho Mary | Director | AWARD | 5,550 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SRZN.
Shares short
2,195,505
Settlement Sep 15, 2026
Change vs prior
+51.9%
Semi-monthly cycle
Days to cover
12.7
At avg daily volume
Of shares outstanding
≈18.7%
Estimate — not % of float
All SRZN filing & press-release reports (4)
- 25-NSE reportAug 7, 2026
- CLUSTER reportMay 5, 2026
- S-3 reportMar 23, 2026
- PRESS-RELEASE reportMar 23, 2026